1Jiang Z, Wu C L, Woda B A ,et al. p504s/alpha-methylacyl-CoA racemase., a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy [J]. Am J Surg Pathol,2002,26 (9): 1169 - 1174.
2Beach R, Gowm A M,De Peralta-Venturina M N,et al. p504s immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies [J]. Am J Surg Pathol, 2002, 26 (12) :1588 - 1596.
3Magi-Galluzzi C, Luo J, Isaacs W CoA racemase : a variably sensitive B, et al. Alpha-methylacylmarker for the diagnosis of small prostate cancer foci on needle biopsy [J] Am J Surg Pathol,2003,27(8) :1128 -1133.
6Jiang Z , Li C , Fisher A, et al. Using an AMACR(p504s)/ 34βE12/p63 cocktail for the detection of small focal protate carcinoma in needle biopsy specimens [J]. Am J Clin Pathol, 2005, 123:231 - 236.
4Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarry. Cancer Res, 2000,60: 1677-1682.
5Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol, 2001, 25: 1397-1404.
6Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol, 2002,26:1588-1596.
7Magi-Galluzzi C, Luo J, Isaacs WB, et al. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol, 2003,27:1128-1133.
8Mostofi FK, Sesterhenn IA, Davis CJ, et al. Histological typing of prostate tumours. WHO, Geneva. Heidelberg: Springer, 2002.
9Chen L, Jiang Z, Woda BA, et al. Decreased expression of alpha-methylacyl-CoA racemase/P504S in foamy gland carcinoma of the prostate. Mod Pathol, 2003, 16: 145A.
10Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol, 2003, 27:772-778.
2Sheridan T, Herawi M, Epstein J I, et al. The role of P501S and PSA in the diagnosis ofmetastatic ade-nocarcinoma ofthe prostate[J]. Am J Surg Pathol, 2007,31(9):1351-5.
3Epstein J I, Egevad L, Humphrey P A, et al. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the international society of urologic pathology consensus conference[J]. Am J Surg Pathol, 2014,38(8):e6-19.
4Hansel D E, Epstein J I. Sarcomatoid carcinoma of the prostate: a study of 42 cases[J]. Am J Surg Pathol, 2006,30(10):1316-21.
5Wang W, Epstein J I. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases[J]. Am J Surg Pathol, 2008,32(1):65-71.
6Ro J Y, Shen S S, Zhai Q J, et al. Advances in surgical pathology: prostate cancer[M]. Philadelpia: LWW Press, 2012:106-18, 211-35.
7Scarpelli M, Mazzucchelli R, Barbisan F, et al. Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase[J]. Int J Immunopathol Pharmacol, 2012,25(1):67-74.
8Yamada H, Tsuzuki T, Maeda N, et al. Alpha methylacyl-CoA racemase(AMACR)in prostate adenocarcinomas from Japanese patients: isAMACR a "race"-dependent marker[J]? Prostate, 2013,73(1):54-9.
9López J I, Schiavo-Lena M, Corominas-Cishek A, et al. Nephrogenic adenoma of the urinary tract: clinical, histological, and immunohistochemical characteristics[J]. Virchows Arch, 2013,463(6):819-25.
10van Leenders G J, Boormans J L, Vissers C J, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice[J]. Mod Pathol, 2011,24(8):1128-38.
